| Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association |
47 |
| Severe hypertriglyceridemia is primarily polygenic |
34 |
| Review of current evidence and clinical recommendations on the effects of low- carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force |
25 |
| Clinical and biochemical features of different molecular etiologies of familial chylomicronemia |
25 |
| Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial |
23 |
| National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk |
18 |
| Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease |
17 |
| Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study |
15 |
| Relationship between LDL-C, estimated true LDL-C, apolipoprotein B- and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide |
14 |
| Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey |
14 |
| Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association |
14 |
| Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis |
13 |
| Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 407 individuals: The EPOCH-JAPAN study |
13 |
| Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia |
12 |
| The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study |
12 |
| Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study |
12 |
| Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size |
11 |
| Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial |
11 |
| Comparison of the effects of flaxseed oil and sunflower seed oil consumption on serum glucose, lipid profile, blood pressure, and lipid peroxidation in patients with metabolic syndrome |
10 |
| PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? |
10 |
| Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis |
10 |
| Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence |
9 |
| Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study |
9 |
| Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span |
9 |
| The association between hypercholesterotemia and sitosterolemia, and report of a sitosterolemia kindred |
9 |
| A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) |
9 |
| Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf |
8 |
| Regulation of angiopoietin-like 4 and lipoprotein lipase in human adipose tissue |
8 |
| A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study |
8 |
| Management of dyslipidemia in adult solid organ transplant recipients |
8 |
| Comparative aspects of the care of familial hypercholesterolemia in the Ten Countries Study |
8 |
| The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data |
8 |
| Clinical and cost benefits of medical nutrition therapy by registered dietitian nutritionists for management of dyslipidemia: A systematic review and meta-analysis |
8 |
| Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study |
8 |
| MFN2-associated lipomatosis: Clinical spectrum and impact on adipose tissue |
7 |
| Circulating oleic acid levels are related to greater risks of cardiovascular events and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis |
7 |
| Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity |
7 |
| Improved endothelial function after short-term therapy with evolocumab |
7 |
| Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals |
7 |
| Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug? |
7 |
| Saturated fatty acids and mortality in patients referred for coronary angiography-The Ludwigshafen Risk and Cardiovascular Health study |
7 |
| Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy |
6 |
| ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia |
6 |
| Assessment of arterial stiffness in patients with familial hypercholesterolemia |
6 |
| Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study |
6 |
| Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk: A community-based cohort study |
6 |
| Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey |
6 |
| Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis |
6 |
| Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials |
6 |
| A common variant in ARHGEF10 alters delta-6 desaturase activity and influence susceptibility to hypertriglyceridemia |
6 |
